This page has only limited features, please log in for full access.

Unclaimed
Ahlam Chaqroun
CNRS, LCPME, Université de Lorraine, 54100 Nancy, France

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

Second year Master student at University of Lorraine-France

Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Review
Published: 18 June 2021 in Viruses
Reads 0
Downloads 0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is genetically variable, allowing it to adapt to various hosts including humans. Indeed, SARS-CoV-2 has accumulated around two mutations per genome each month. The first relevant event in this context was the occurrence of the mutant D614G in the Spike gene. Moreover, several variants have emerged, including the well-characterized 20I/501Y.V1, 20H/501Y.V2, and 20J/501Y.V3 strains, in addition to those that have been detected within clusters, such as 19B/501Y or 20C/655Y in France. Mutants have also emerged in animals, including a variant transmitted to humans, namely, the Mink variant detected in Denmark. The emergence of these variants has affected the transmissibility of the virus (for example, 20I/501Y.V1, which was up to 82% more transmissible than other preexisting variants), its severity, and its ability to escape natural, adaptive, vaccine, and therapeutic immunity. In this respect, we review the literature on variants that have currently emerged, and their effect on vaccines and therapies, and, in particular, monoclonal antibodies (mAbs). The emergence of SARS-CoV-2 variants must be examined to allow effective preventive and curative control strategies to be developed.

ACS Style

Ahlam Chaqroun; Cédric Hartard; Evelyne Schvoerer. Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants. Viruses 2021, 13, 1171 .

AMA Style

Ahlam Chaqroun, Cédric Hartard, Evelyne Schvoerer. Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants. Viruses. 2021; 13 (6):1171.

Chicago/Turabian Style

Ahlam Chaqroun; Cédric Hartard; Evelyne Schvoerer. 2021. "Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants." Viruses 13, no. 6: 1171.